Last updated: August 3, 2020
The real battle against cancer is fought by physicians and patients!
Our mission is simply to provide healthcare professionals
with innovative tools that are the most reliable and effective possible.
In cancer, hPG80 is overexpressed in the tumor and detectable in the patient’s blood. 16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.
Cancer stem cells express elevated levels of hPG80 (circulating progastrin).
Secretion of hPG80 maintain tumor-initiating and self-renewal capabilities of cancer stem cells.
hPG80 is released from the tumor and becomes detectable in the blood across all stages.
Plasma hPG80 is elevated in a wide range of cancer patients
hPG80 is produced by all cancer cells, but in quantities 100 to 1000 times higher by cancer stem cells, making hPG80 the only blood biomarker that gives information on tumor activity.
. You et al, EBioMedicine, 2020 Jan;51:102574
. Giraud et al, Cancer Res, 2016;76(12):3618-28
. Siddheshwar et al, Gut, 2001 Jan; 48(1): 47–52
. Prieur et al, Clin Cancer Res. 2017;23(17):5267–5280
. Konieczkowski et al, Cancer Cell, 2018 May 14;33(5):801-815
CURRENT AND PROSPECTIVE
hPG80 measurement, and its trend, from simple blood samples, can help Physicians in the follow-up of patients, providing them with additional meaningful information on:
risk of minimal residual disease,
risk of relapse.
The presence or absence of hPG80 in blood can also provide Physicians with an additional indicator of vigilance for earlier diagnosis, especially for at-risk populations and for cancers for which no biomarker exists.
In addition, other potential uses for hPG80 are being investigated and will be available to physicians in a few years:
hPG80 neutralization has shown that it can lead to a new clinical approach to tumor reversion therapy that causes cancer cells to return to “normal”,
hPG80 can provide a major breakthrough in tumor localization by PET Scan imaging,
Finally, the robustness of its detection in blood makes it possible to envisage in the short term the production of a hPG80 rapid test providing physicians and health authorities with a new affordable and very minimally invasive tool that could help them in their early detection strategies.
NOW AVAILABLE TO PHYSICIANS
A NEW TOOL :
AVAILABLE ONLY ON MEDICAL PRESCRIPTION